P/E ratio for NuVasive (NUVA)
P/E ratio as of April 2024 (TTM): 73.6
According to NuVasive's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 73.6111. At the end of 2022 the company had a P/E ratio of 53.6.
P/E ratio history for NuVasive from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 53.6 | -227.57% |
| 2021 | -42.0 | -44.85% |
| 2020 | -76.1 | -223.03% |
| 2019 | 61.9 | -70.04% |
| 2018 | 207 | 471.94% |
| 2017 | 36.1 | -60.34% |
| 2016 | 91.0 | 128.79% |
| 2015 | 39.8 | -131.22% |
| 2014 | -127 | -170.96% |
| 2013 | 180 | -7.06% |
| 2012 | 193 | -2740.11% |
| 2011 | -7.32 | -156.79% |
| 2010 | 12.9 | -94.36% |
| 2009 | 228 | -601.03% |
| 2008 | -45.6 | -61.93% |
| 2007 | -120 | 651.73% |
| 2006 | -15.9 | 7.38% |
| 2005 | -14.8 | 306.73% |
| 2004 | -3.65 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Medtronic MDT | 29.6 | -59.85% | 🇮🇪 Ireland |
 Stryker Corporation SYK | 49.5 | -32.80% | 🇺🇸 USA |
 Orthofix Medical
OFIX | -3.70 | -105.03% | 🇺🇸 USA |
 Globus Medical GMED | 25.2 | -65.74% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.